Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients.

BACKGROUND: Safety concerns have been raised about the use of adjuvanted vaccines after kidney transplantation. METHODS: We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010. RESULTS: Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination. CONCLUSION: Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.

[Imported malaria and HIV infection in Madrid. Clinical and epidemiological features]. / Paludismo importado e infección por VIH en Madrid. Perfil clínico y epidemiológico.

INTRODUCTION: Few data are available in Spain data on human immunodeficiency virus (HIV) patients coinfected with malaria. This study has aimed to determine the epidemiological and clinical characteristics of imported malaria in patients coinfected with HIV. PATIENTS AND METHODS: A case-series retrospective study was performed using the patient's medical records. The study population consisted on patients diagnosed with malaria attended in our center from january 1, 2002 to december 31, 2007. RESULTS: A total of 484 episodes of malaria, 398 of which were included in this study, were identified. Co-infection with HIV was described in 32 cases. All of them occurred in individuals presumably with some degree of semi-immunity. In the coinfected group, there were 13 cases (40.6%) asymptomatic, whereas this event occurred in 99 cases of patients not coinfected (37.2%) (P=0.707). The greater presence of anemia in co-infected patients (62.5% vs 32.3% in non-coinfected [P=0.001]) stands out. CONCLUSIONS: In present study, the clinical presentation forms were similar, regardless of the presence or absence of HIV infection. Although the study population does not reflect all possible scenarios of malaria and HIV coinfection, our results indicate the reality of patients attended in the Autonomous Community of Madrid.

[Imported malaria in adults. Clinical, epidemiological and analytical features]. / Paludismo importado en adultos. Perfil clínico, epidemiológico y analítico.

INTRODUCTION: Up to now, the epidemiological and clinical features of imported malaria in Spain have been described in small series from general hospitals. Almost all diagnosis had been made based on symptomatic patients. The aim of this study has been to determine the epidemiological, clinical and laboratorial characteristics of imported malaria in a Reference Unit for Tropical Diseases. PATIENTS AND METHODS: We performed a cross-sectional, observational and retrospective study. The series consisted of patients diagnosed of malaria who had been attended at the Hospital Carlos III from January 1, 2002 to December 31, 2007. RESULTS: We identified 484 episodes of malaria, of which 398 cases were included in the analysis. Almost 50% of the patients were natives of endemic areas, while the rest were native-travelers or travelers. Most cases (88-98% according to the group) had not taken malaria chemoprophylaxis correctly when indicated. At the time of diagnosis, 30.4% of patients were asymptomatic and 28.1% of asymptomatic patients had anemia, 19.8% thrombocytopenia, 14% leukopenia, 5% hypocholesterolemia, 5% renal failure and 4.1% hypoglycemia. Low parasitemia was present in 97.5% of asymptomatic individuals compared to 80.5% of the symptomatic patients (P<0.001). DISCUSSION: Absence of chemoprophylaxis (or poor compliance) is the main reason for malaria in individuals traveling to endemic areas. Malaria must be ruled out in individuals coming from tropical countries with compatible symptoms, and it also should be suspected in certain groups of asymptomatic individuals with abnormal laboratorial parameters.

Influenza vaccination coverage among hospital personnel over three consecutive vaccination campaigns (2001-2002 to 2003-2004).

This study was carried out to assess influenza vaccination coverage among hospital personnel and the impact of health promotion campaigns, within the hospital, designed to increase vaccination coverage over three consecutive vaccination campaigns (2001-2002 to 2003-2004). The health promotion tool used in the 2001-2002 and 2002-2003 were informative posters distributed throughout the hospital. In the 2003-2004 season, the recommendation was also published in the internal bulletin and Web site of the hospital. In addition, a physician and a nurse from the Department of Preventive Medicine visited all departments offering vaccination in the work place. The overall vaccination coverage in the 2001-2002 campaign was 16% with coverage of 11.5% in nurses and 15% in physicians. In the 2002-2003 and 2003-2004 campaigns the overall vaccination coverage was 21% and 40%, respectively (p<0.01). Staff physicians and resident physicians reached 60 and 42% coverage rates in the 2003-2004 campaign, but coverage in nurses and nursing assistant remained around 30% (p<0.01). In summary, influenza vaccination coverage among hospital based healthcare personnel increased significantly during the last three seasons, however, it still remains low despite active attempts at promoting influenza vaccination.

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.

BACKGROUND: Due to their impaired immune system, patients with renal insufficiency have a suboptimal response to hepatitis B (HB) vaccination and frequent boosters are needed to maintain protection. GlaxoSmithKline Biologicals has developed a HB vaccine containing a new adjuvant system AS04 for use in this immunocompromised patient population. METHODS: In an open, randomized clinical trial conducted in pre-hemodialysis (documented creatinine clearance < or =30 mL/min) and hemodialysis patients, over 15 years of age and naïve for HB, the immunogenicity and safety of single doses of HB-AS04 (Fendrix, GlaxoSmithKline Biologicals) were compared to double doses of commercially available HB vaccine (Engerix, GlaxoSmithKline Biologicals) administered at 0, 1, 2, and 6 months, and followed-up for 36 months. RESULTS: The HB-AS04 vaccine elicited a more rapid onset of protection than the currently licensed vaccine for this particular population, with 74% versus 52% of subjects seroprotected at month 3. After the vaccination course, seroprotection rates increased to 91% versus 84% in the HB-AS04 and standard vaccine groups, respectively. Differences persisted up to 36 months post-vaccination (73% vs. 52%, respectively). Antibody concentrations were higher following the HB-AS04 vaccine at all post-vaccination time points. During the follow-up, significantly fewer subjects primed with the HB-AS04 vaccine needed a booster dose as a consequence of anti-HBs loss below seroprotective levels (11/62 subjects in the HB-AS04 group vs. 22/57 subjects in the standard vaccine group, respectively, P = 0.014). The HB-AS04 was more locally reactogenic than the standard immunization regimen, with pain at the injection site occurring with 41% of HB-AS04 doses versus 19% of standard vaccine doses. The occurrence of grade 3 pain was less than 1% in both groups and all events resolved within the 4-day follow-up period. CONCLUSION: The improved immunogenicity profile and clinically acceptable reactogenicity of HB-AS04 vaccine are of key importance to provide a more rapid, enhanced, and longer seroprotection to these immunocompromised patients at risk for HB infection.

Seroprevalence of varicella antibodies in healthcare workers and health sciences students. Reliability of self-reported history of varicella.

The objective of this study was to assess the seroprevalence of varicella antibodies in healthcare workers and students of healthcare professions and to determine the validity of the self-reported varicella history for detecting susceptible subjects. Personnel of a general hospital and students were recruited and a 5 mL blood sample was obtained from all participants. A case report form, including previous self-reported history of varicella, was completed. A total of 91 healthcare workers (mean age, 30.6 years; S.D., 4.0; range, 23-40) and 92 students (mean age, 19.8 years; S.D., 2.5; range, 18-25) were recruited. The prevalence of varicella antibodies was 91.2% in healthcare workers and 92.1% in students. Overall, the sensitivity, specificity, positive and negative predictive values of a self-reported history of varicella were 68.4%, 66.7%, 95.4% and 17.2%, respectively. The preferred approach in these groups at risk of varicella will be to undergo serologic testing before immunization in those with negative or unknown history of varicella.

Cost analysis of two strategies for hepatitis A vaccination of hospital health-care personnel in an intermediate endemicity area.

The aim of the study was to carry out a cost analysis to allow the comparison of the cost of two vaccination strategies against Hepatitis A in health-care personnel. A total of 423 health-care workers were recruited at one General Hospital of Madrid, Spain. Blood specimens were obtained for anti-HAV antibody determination. The prevalence of anti-HAV antibody was 40% (95% CI: 35-45) and it was directly correlated with age. Cost analysis determined that the critical value of prevalence for vaccination with HAV vaccine was 23%. In hospital health-care workers < or =30 years in age, vaccination with HAV vaccine (without screening) would be the less costly strategy. In those >30 years in age, it would be less costly to screen for anti-HAV antibody first and vaccinate those who are antibody-negative.

Hepatitis B vaccination results in 140 liver transplant recipients.

BACKGROUND/AIMS: Human autologous liver transplantation is possible due to an adequate suppression of the body's immune response. This also causes a higher hepatitis infection rate, making hepatitis prevention very important. MATERIALS AND METHODS: We describe our experience with hepatitis B virus vaccination in 140 adult liver transplant recipients, transplanted from 1986 to 1994 with more than one year of follow-up. Excluded were those who had hepatitis B surface antigens or antibodies to those antigens before the transplant. The vaccination schedule was 0-1-2 months with a double dose of recombinant vaccine. RESULTS: The total response rate (surface antigen antibodies > 10 U) was 40% (56/140); the rate was 47.7% in men and 26% in women. At the end of the study, only 17.1% (24/140) of the patients had antibodies > 10 U. The response rate was higher in patients with antibodies to hepatitis B core antigen (66.6%) than in those lacking antibodies (31.7%), and more long lasting (42.4% vs 11.2%). The response rate in 116 patients with booster doses was 12.9%. Six correctly vaccinated patients (4.28%) acquired new hepatitis B virus infections after the operation. CONCLUSIONS: The total response rate in these patients is much lower than in the general population, and there is a rapid decline of titers, probably due to immunosuppression. The role of booster doses in these patients should be clarified.

Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus.

A study was conducted to investigate the immunogenicity of a recombinant DNA hepatitis B vaccine in neonates and children of HIV-infected women. Immunization against hepatitis B consisted of three 10 micrograms doses of the vaccine administered on a 0-, 1- and 6-month schedule. The children were followed up for an average of 11 months. Of the 118 HIV-positive neonates who participated in the study, 95 lost their HIV antibodies during the follow-up period. Most (94.2%) of the latter who completed the study responded to the vaccine. Of the 23 who remained HIV-positive, 17 completed the study and 7 produced hepatitis B antibodies.

Dental health of Spanish children: an investigation in primary care.

The oral hygiene of patients between seven and 14 years old from a health centre in Toledo was studied through case-finding from March to December 1987. A total of 304 interviews were held; bad dental care (frequency of teeth brushing with fluoride toothpaste less than once per day and/or daily consumption of chocolate and sweets) was found in 83%, and caries were diagnosed through inspection in 92% of the patients. Seventy three per cent reported washing their teeth only occasionally or never; 40% consumed sweets daily; 53% had never visited the dentist; and 50% had not received preventive care for dental disease. These results contrast with those from the United Kingdom and other developed countries, indicating a precarious state of dental health in Spain, a fact which should be taken into account by the Spanish health organization when comparing the health levels between different countries.

[Health education in obesity: evaluation of the efficacy of a program]. / Educación sanitaria en la obesidad: evaluación de la eficacia de un programa.

A program for weight reduction in obese individuals detected in a general practice was evaluated and compared with alternative usual types of management. From March to December 1987 the index of body mass (IBM) was systematically measured in 790 individuals older than 15 and younger than 65 years who attended a general practice. 42% of them had IBM higher than 25 and were considered as obese, being then randomly assigned to an experimental or a control groups. In the first group, educational counselling to lose weight based on health information was offered, hypocaloric diet was given, and motivational support during follow up was provided, mainly by nurses. The results in 155 individuals (63 cases and 92 controls) free from confusing factors and followed up for a mean period of 239 days were evaluated. The cases demonstrated a higher degree of information and lost more weight. The effectiveness of the experimental program was 22%, while that of routine management was 8%. The difference in success rates was 15.7% (95% C.I.: 28.5%, 2.9%), favoring the experimental group.

[Use of drugs in a sample of users in primary health care]. / Consumo de medicamentos en una muestra de los usuarios de la Atención Primaria.

A study is made of the consumption of medicines in relation to the professionals who recommend them, and the degree of compliance in their ingestion, amongst the users of Primary Attention, by means of a method of case detection made on patients over the age of 25, who personally visited a General Medicine doctor between March and December, 1987. 703 interviews were carried out, with the result that 41% of the patients took medicines prescribed at that visit, with an average of 0.69 per person, and 0.45 medicines with chronic dosage. 7.3% used medicines prescribed by private doctors, and 2.2% prescribed by non-medical professionals. These results suggest a moderately high and chronic consumption which ought to be taken into account in the local planning of future educational programs, in order to improve the use of medicines in the community.